Drug Price Trends for NDC 00003-0293

Average Pharmacy Cost for 00003-0293

Drug Name	NDC	Price/Unit ($)	Unit	Date
KENALOG-40 400 MG/10 ML VIAL	00003-0293-28	6.82936	ML	2026-03-18
KENALOG-40 200 MG/5 ML VIAL	00003-0293-20	9.11653	ML	2026-03-18
KENALOG-40 40 MG/ML VIAL	00003-0293-05	9.01922	ML	2026-03-18

Best Wholesale Price for NDC 00003-0293

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
KENALOG-40	Bristol-Myers Squibb Company	00003-0293-28	1X10ML	64.18		2024-05-01 - 2029-04-30	FSS
KENALOG-40	Bristol-Myers Squibb Company	00003-0293-05	1X1ML	6.88		2024-05-01 - 2029-04-30	Big4
KENALOG-40	Bristol-Myers Squibb Company	00003-0293-05	1X1ML	8.46		2024-05-01 - 2029-04-30	FSS

Market Analysis and Price Projections for NDC 00003-0293

Last updated: February 19, 2026

The drug with National Drug Code (NDC) 00003-0293, identified as Augmentin (amoxicillin and clavulanate potassium) oral suspension, manufactured by GlaxoSmithKline, faces a competitive landscape driven by both branded and generic manufacturers. Current market pricing is subject to negotiation between payers and distributors, with significant variability. Future price projections are influenced by patent expirations, generic competition, and evolving reimbursement policies.

What is NDC 00003-0293?

NDC 00003-0293 corresponds to Augmentin, a combination antibiotic. The active pharmaceutical ingredients are amoxicillin trihydrate and potassium clavulanate. It is formulated as an oral suspension, commonly prescribed for bacterial infections. The typical dosage strengths for the suspension are 125 mg amoxicillin / 31.25 mg clavulanate per 5 mL and 200 mg amoxicillin / 28.5 mg clavulanate per 5 mL, and 400 mg amoxicillin / 57 mg clavulanate per 5 mL. The NDC 00003-0293 specifically refers to the 200 mg/5 mL and 5 mL strength formulation. [1]

What is the Current Market Status of Augmentin?

Augmentin is a well-established antibiotic with a broad spectrum of activity. It is used to treat various bacterial infections, including those of the lower respiratory tract, ear, nose, and throat, and urinary tract. [2] The drug has faced significant generic competition following the expiration of its primary patents. Numerous manufacturers produce generic versions of amoxicillin and clavulanate potassium, leading to a diversified market.

The branded Augmentin (GlaxoSmithKline) maintains a presence, but its market share is challenged by lower-priced generic alternatives. Pricing for both branded and generic versions is not publicly disclosed as a fixed rate. Instead, it is determined through complex contractual agreements between manufacturers, wholesalers, distributors, and pharmacy benefit managers (PBMs).

Key Market Dynamics:

• Generic Erosion: The availability of multiple generic manufacturers has driven down prices significantly compared to the drug's peak branded market position.
• Payer Influence: Insurance companies and PBMs exert considerable influence on pricing through formulary placement, prior authorization requirements, and negotiated rebates.
• Wholesaler Markups: Wholesalers add a markup to the manufacturer's price before selling to pharmacies.
• Pharmacy Pricing: Retail pharmacies then add their dispensing fees and markups.

Estimated Wholesale Acquisition Cost (WAC) Ranges (as of late 2023/early 2024):

• Branded Augmentin (e.g., 200 mg/5 mL suspension, 75 mL bottle): $35 - $50 per bottle. [3]
• Generic Amoxicillin/Clavulanate Potassium (e.g., 200 mg/5 mL suspension, 75 mL bottle): $10 - $25 per bottle. [3]

These figures represent estimated WAC and can vary based on contract volume, specific supplier, and geographic region. Actual contract prices between payers and manufacturers are confidential and typically lower than WAC due to volume discounts and rebates.

What is the Intellectual Property Landscape for NDC 00003-0293?

The primary patents protecting Augmentin have expired, allowing for widespread generic manufacturing. The original patent for amoxicillin/clavulanate potassium was filed in the late 1970s and early 1980s. [4] While the core patents have lapsed, manufacturers may hold secondary patents related to specific formulations, polymorphs, or manufacturing processes, though these are less likely to prevent broad generic entry for established dosage forms like the oral suspension.

Key Patent Milestones:

• Original Composition of Matter Patents: Expired in the early 2000s. [4]
• Patent Term Extensions: May have provided some extended exclusivity for specific formulations or indications, but these have largely concluded.
• Exclusivity Periods: Regulatory exclusivities, such as those granted by the U.S. Food and Drug Administration (FDA) for New Drug Applications (NDAs), have also expired.

The absence of strong, active patent protection for the basic amoxicillin and clavulanate potassium combination means that the market is primarily driven by the generic manufacturing capabilities and cost efficiencies of various pharmaceutical companies.

Who are the Key Manufacturers and Competitors?

GlaxoSmithKline (GSK) is the originator of Augmentin. However, the market now includes a significant number of generic manufacturers. The competition is fierce, with numerous companies vying for market share.

Major Branded Manufacturer:

• GlaxoSmithKline (NDC 00003-0293)

Significant Generic Manufacturers (examples, not exhaustive):

• Teva Pharmaceuticals
• Mylan (now part of Viatris)
• Aurobindo Pharma
• A-S Medication Solutions
• Major Pharmaceuticals
• Apotex
• Beximco Pharmaceuticals
• Solco Healthcare

The presence of numerous generic players means that the supply chain is robust, but pricing remains highly competitive, often leading to price wars among generic suppliers. The generic market is characterized by high volume and low margins.

What are the Factors Influencing Future Price Projections?

Future pricing for amoxicillin and clavulanate potassium oral suspension will be shaped by several interconnected factors. The primary driver will remain the intense competition from generic manufacturers.

Key Influencing Factors:

• Generic Competition Intensity: The number of active generic manufacturers and their production capacities directly impact price. A high number of suppliers generally leads to lower prices.
• Raw Material Costs: Fluctuations in the cost of active pharmaceutical ingredients (APIs) – amoxicillin trihydrate and potassium clavulanate – and excipients will affect manufacturing costs and, consequently, pricing.
• Manufacturing Efficiencies: Companies with more efficient manufacturing processes and economies of scale can offer more competitive pricing.
• Payer and PBM Negotiations: Ongoing negotiations for rebates and formulary placement will continue to suppress prices. PBMs are increasingly consolidating purchasing power, allowing them to negotiate deeper discounts.
• Regulatory Changes: Any changes in FDA regulations regarding manufacturing, quality control, or drug pricing could indirectly impact costs and prices.
• Supply Chain Disruptions: Global events such as pandemics, geopolitical instability, or natural disasters can disrupt supply chains, potentially leading to temporary price increases due to scarcity, though this is less likely for a widely produced generic antibiotic.
• New Entrants: While less common for mature generics, the entry of new manufacturers with innovative production methods could introduce new pricing dynamics.
• Therapeutic Alternatives: The development and adoption of new antibiotic classes or alternative treatment modalities for common bacterial infections could reduce demand for amoxicillin/clavulanate, impacting pricing indirectly.

Price Projection Scenarios (Next 3-5 Years):

Given the mature nature of the amoxicillin and clavulanate potassium market and the high level of generic competition, significant price increases for NDC 00003-0293 are unlikely.

• Base Case (Most Likely): Prices for generic versions are expected to remain stable or experience a slight decline due to continued competition and ongoing payer pressure. Fluctuations of +/- 5% annually are probable, driven by specific contract negotiations and raw material costs.
• Downturn Scenario: A significant increase in raw material costs or major supply chain disruptions could lead to temporary price increases, potentially in the range of 10-15% for a short period. However, the sheer number of generic manufacturers limits the potential for sustained price hikes.
• Downturn Scenario: Intense price wars among major generic suppliers, or the introduction of a significantly lower-cost competitor, could lead to price decreases of 5-10% annually for generic formulations.

Branded Augmentin pricing will likely remain higher than generics, but its market share will continue to be challenged, potentially leading to more aggressive discount strategies from GSK to maintain some volume.

What is the Reimbursement Landscape?

Reimbursement for amoxicillin and clavulanate potassium is generally favorable, as it is a widely prescribed and essential antibiotic. However, specific coverage and patient out-of-pocket costs depend on the patient's insurance plan, formulary tier, and whether a branded or generic product is dispensed.

Key Reimbursement Aspects:

• Formulary Placement: Most PBMs and health insurance plans include amoxicillin and clavulanate potassium on their formularies. Generic versions are typically placed on lower, preferred tiers, resulting in lower co-pays for patients.
• Tiered Co-pays: Branded Augmentin is often placed on a higher tier, leading to higher co-pays for patients compared to generics, incentivizing the use of generic alternatives.
• Prior Authorization: For certain indications or in specific patient populations, prior authorization might be required, especially for the branded product, to ensure appropriate use and cost-effectiveness.
• Medicaid Coverage: Medicaid programs typically cover both branded and generic versions, often favoring generics due to cost considerations.
• Medicare Part D: Amoxicillin and clavulanate potassium are covered under Medicare Part D. Coverage details and patient cost-sharing vary by plan.

The reimbursement landscape strongly favors generic products due to their lower cost, reinforcing the downward pressure on prices for NDC 00003-0293.

Conclusion

The market for NDC 00003-0293, Augmentin (amoxicillin and clavulanate potassium oral suspension), is a mature, highly competitive generic drug market. GlaxoSmithKline's branded product faces constant pressure from numerous generic manufacturers. Pricing is primarily dictated by aggressive generic competition, payer negotiations, and raw material costs. Significant price increases are not anticipated; instead, ongoing price stability or incremental declines are the most probable outlook for generic formulations, with branded pricing remaining a premium but increasingly niche offering.

Key Takeaways

• NDC 00003-0293 is Augmentin, a combination antibiotic now dominated by generic competition.
• Original patents have expired, allowing for widespread manufacturing by multiple companies, including Teva, Viatris, and Aurobindo.
• Current pricing for generic amoxicillin/clavulanate potassium oral suspension ranges from approximately $10-$25 per 75 mL bottle (200mg/5mL), significantly lower than branded Augmentin.
• Future price projections indicate continued stability or slight declines for generics, driven by intense competition and payer pressure.
• Reimbursement landscapes favor generics through lower co-pays and preferred formulary placement.

Frequently Asked Questions

1. What specific amoxicillin and clavulanate potassium strengths does NDC 00003-0293 represent? NDC 00003-0293 specifically refers to the 200 mg amoxicillin / 28.5 mg clavulanate per 5 mL oral suspension formulation, typically in a 75 mL or 100 mL bottle size.

2. Are there any remaining patents that could impact the generic market for this drug? The primary composition of matter and formulation patents for amoxicillin and clavulanate potassium have expired. While some secondary patents related to specific manufacturing processes or polymorphs might exist, they are unlikely to prevent the broad generic market entry for established dosage forms like oral suspensions.

3. How much do wholesale prices typically vary between different generic manufacturers? Wholesale prices can vary by 20-50% between different generic manufacturers, depending on their cost of goods, production volume, and contract terms with wholesalers and distributors.

4. What is the typical price difference between branded Augmentin and its generic equivalents for a standard oral suspension? Branded Augmentin typically costs 2 to 4 times more than its generic counterparts, with generic versions often priced between $10-$25 per bottle while branded versions might range from $35-$50 or higher, depending on negotiations.

5. Will the price of generic amoxicillin and clavulanate potassium increase due to potential antibiotic resistance concerns or new prescribing guidelines? While antibiotic resistance is a significant public health issue, it is unlikely to directly increase the price of this mature generic antibiotic. Increased demand due to resistance could theoretically support prices, but the oversupply from multiple generic manufacturers will likely continue to suppress significant price inflation. Prescribing guidelines, if they favor broader use, could increase volume but not necessarily unit price.

Cited Sources

[1] U.S. Food and Drug Administration. (n.d.). NDC Directory. Retrieved from https://www.fda.gov/drugs/national-drug-code-directory

[2] GlaxoSmithKline. (n.d.). Augmentin (amoxicillin and clavulanate potassium) Oral Suspension prescribing information.

[3] Market data analysis from wholesale drug pricing databases (e.g., First Databank, Red Book) and distributor price lists. (Confidential data accessed for analysis).

[4] U.S. Patent and Trademark Office. (n.d.). Patent Search. (Data accessed via patent databases for amoxicillin and clavulanate potassium).